15 studies found for:    RPE65
Show Display Options
Rank Status Study
1 Completed Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65
Condition: Leber Congenital Amaurosis
Intervention: Drug: rAAV2/4.hRPE65
2 Active, not recruiting
Has Results
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
Condition: Leber Congenital Amaurosis
Intervention: Biological: rAAV2-CB-hRPE65
3 Recruiting Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
Condition: Leber Congenital Amaurosis
Intervention: Genetic: rAAV2-hRPE65
4 Active, not recruiting Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations
Conditions: Amaurosis of Leber;   Retinal Diseases
Intervention: Genetic: rAAV2-CBSB-hRPE65
5 Completed Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT
Conditions: Leber Congenital Amaurosis (LCA);   Retinitis Pigmentosa (RP)
Intervention: Other: No treatment: retrospective chart review
6 Recruiting Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
Condition: Leber Congenital Amaurosis
Intervention:
7 Completed Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)
Condition: Retinitis Pigmentosa (RP)
Intervention: Drug: QLT091001
8 Active, not recruiting Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
Conditions: Inherited Retinal Dystrophy Due to RPE65 Mutations;   Leber Congenital Amaurosis
Intervention: Biological: AAV2-hRPE65v2
9 Completed Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations
Conditions: LCA (Leber Congenital Amaurosis);   RP (Retinitis Pigmentosa)
Intervention: Drug: QLT091001
10 Completed Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis
Condition: Retinal Degeneration
Intervention: Biological: tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)
11 Recruiting Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Condition: Leber Congenital Amaurosis
Intervention: Genetic: AAV2/5 OPTIRPE65
12 Active, not recruiting Safety Study in Subjects With Leber Congenital Amaurosis
Condition: Leber Congenital Amaurosis
Intervention: Biological: AAV2-hRPE65v2
13 Active, not recruiting Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
Condition: Leber Congenital Amaurosis
Intervention: Biological: AAV2-hRPE65v2
14 Completed Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
Conditions: LCA (Leber Congenital Amaurosis);   RP (Retinitis Pigmentosa)
Intervention: Drug: QLT091001
15 Completed Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy
Conditions: Amaurosis;   Retinal Diseases
Interventions: Procedure: realization of a family tree;   Procedure: refractometry;   Procedure: evaluation of the presence of a nystagmus;   Procedure: ocular behavior;   Procedure: test of baby vision;   Procedure: test of keenness;   Procedure: reading test;   Procedure: visual field;   Procedure: color vision;   Procedure: electroretinographical activity;   Procedure: biomicroscopical test;   Procedure: retinal imaging;   Procedure: retinal autofluorescence;   Procedure: genotyping

Indicates status has not been verified in more than two years